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OBJECTIVES We sought to assess the effect of glycoprotein (GP) IIb/IIIa blockade on myocardial platelet
and polymorphonuclear leukocyte accumulation and on infarct size after coronary injury and
transient coronary occlusion (CO) in pigs.
BACKGROUND It has been suggested that platelet GP IIb/IIIa blockade might reduce the severity of
microvascular damage after reperfusion.
METHODS Sixteen thiopental-anesthetized, open-chest pigs, in whom platelets had been labeled with
technetium-99m (99mTc) on the previous day, were submitted to catheter-induced left anterior
descending coronary artery (LAD) injury followed by 55 min of CO and 5 h of reperfusion. Five
minutes before reflow, the animals were blindly allocated to receive lamifiban (intravenous bolus
of 250 g/kg body weight and continuous infusion of 3 g/kg per min) or saline.
RESULTS Lamifiban had a rapid and potent platelet anti-aggregatory effect, as demonstrated by
significant prolongation of the bleeding time and profound (90%) inhibition of ex vivo
platelet aggregation, and completely prevented the development of cyclic flow reductions of
the LAD (0 vs. 5  1, one of them followed by re-occlusion, in control animals, p  0.005).
However, compared with animals receiving placebo, those treated with lamifiban had a
similar (p  NS) content of 99mTc platelets in the reperfused myocardium (288  40% vs.
205  27% of the value in the control region, respectively) and similar myeloperoxidase
activity (0.50  0.17 U/g vs. 0.47  0.17 U/g, respectively) and infarct size (46.8  12.0%
vs. 49.8 10.5% of the area at risk, respectively). Arteriolar platelet thromboemboli were very
rarely seen on histologic analysis. Lamifiban did not modify platelet P-selectin expression in
additional studies.
CONCLUSIONS Platelet GP IIb/IIIa blockade has a potent antithrombotic effect at the culprit lesion, but does
not significantly reduce the magnitude of microvascular platelet accumulation or myocardial
damage after transient CO. (J Am Coll Cardiol 2002;39:157–65) © 2002 by the American
College of Cardiology
Reperfusion strategies have led to a dramatic improvement
in the prognosis of patients with acute myocardial infarc-
tion. However, the beneficial effect of successful restoration
of coronary flow on myocardial salvage may be hampered by
inadequate tissue perfusion (1–3). Recovery of myocardial
flow after coronary reperfusion may be compromised, espe-
cially in areas of severe ischemic damage, by intravascular
plugging of polymorphonuclear leukocytes (PMNs), depo-
sition and aggregation of platelets or edema (4–10). In
addition, periodic dislodgment of the culprit coronary
thrombus might result in distal embolization, causing addi-
tional microvessel obstruction (11,12).
Among several strategies that have been developed to
increase the benefits of coronary reperfusion by reducing the
severity of microvascular obstruction, platelet glycoprotein
(GP) IIb/IIIa blockade appears to be one of the most
promising. Besides promoting a more rapid and stable
infarct artery patency when administered as an adjunct to
reperfusion therapy (13,14), recent clinical data suggest that
GP IIb/IIIa inhibitors could directly improve microvascular
perfusion (15,16). However, experimental data supporting
this hypothesis are scarce (17–20), and little is known about
the effects of GP IIb/IIIa blockade on microvascular blood
cell deposition and on myocardial salvage after transient
coronary occlusion (CO) in vivo.
Accordingly, the present study tested whether lamifiban,
a potent and selective GP IIb/IIIa inhibitor (13), adminis-
tered during reperfusion, was able to reduce the magnitude
of myocardial platelet or PMN accumulation or infarct size
after coronary injury and transient CO in swine.
METHODS
Animal preparation. After approval by the Institutional
Research Commission, and in accordance with the Position
of American Heart Association on Research Animal Use,
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adopted by the Association in November 1984, 19 farm pigs
of either gender, weighing 25  1 kg, were sedated with
10 mg/kg of azaperone intramuscularly, anesthetized with
10 mg/kg of thiopental intravenously, intubated and con-
nected to a mechanical ventilator supplying room air.
Anesthesia was maintained with a continuous infusion of
thiopental. One femoral artery and both femoral veins were
catheterized; the right carotid artery was dissected; a ster-
notomy was performed; and the pericardium was opened.
The left anterior descending coronary artery (LAD) was
dissected free at its mid segment and surrounded by a snare.
Study groups and protocol. The LAD was injured, as
previously described (10,21), by means of an intracoronary
Cordis 2.5F catheter (Miami, Florida) introduced through
the carotid artery, to stimulate the development of mural
thrombosis. After this injury, the LAD was ligated for 55
min, followed by 5 h of reflow. Five minutes before
reperfusion, the animals were randomly allocated to re-
ceive—blindly to the investigators performing the experi-
ments—lamifiban (250 g/kg body weight IV followed by a
continuous infusion of 3 g/kg per min, a dose that had
shown to cause profound inhibition of platelet aggregation
in this model) or saline. Three animals were excluded before
randomization: two due to severe hypotension and one due
to occlusion of the left main coronary artery during cathe-
terization. Therefore, 16 animals, 8 receiving lamifiban and
8 receiving placebo, were included.
Study monitoring. Serial arterial blood gases were ob-
tained to adjust the ventilatory variables. Aortic blood
pressure was continuously monitored with a crystal quartz
transducer and LAD flow with an electromagnetic flowme-
ter (MDL-1401, Skalar, Holland). These signals, along
with lead II of the electrocardiogram, were amplified and
continuously recorded at a sampling rate of 200 Hz per
channel on a thermic pad recorder (Astro-Med MT9500,
West Warwick, Rhode Island). Cyclic flow reductions
(CFRs) were defined as progressive reductions in blood flow
at the mid LAD over a period of minutes, followed by
abrupt increases in blood flow with an amplitude of at least
25% of the maximal blood flow value (22). When ventric-
ular fibrillation occurred, it was converted to sinus rhythm
by internal shocks of 10 to 20 J.
Bleeding time and ex vivo platelet aggregometry. Serial
measurements of bleeding time and platelet aggregation
were performed to assess the effect of lamifiban. A small
incision was made on one ear of the animal, as previously
described (21), and the time until bleeding ceased was
measured. Two measurements were performed at each one
of these time points: before CO, before treatment initiation,
and 15 min, 1 h, and 2 h after treatment initiation. The
mean value of each pair was calculated and used for analysis.
At these time points, venous blood was withdrawn and
processed as previously described (21) to obtain platelet-rich
plasma. The platelet count (System-8000, Baker Instru-
ments, Allentown, Pennsylvania) in platelet-rich plasma
was maintained350 103 platelets/l by adding platelet-
poor plasma. The platelet-rich plasma was distributed into
0.45-ml siliconized cuvettes and warmed to 37°C. Platelet
aggregation was induced by addition of 10 mol/l of
adenosine diphosphate (ADP) in saline (21) and was mea-
sured in a four-channel aggregometer (Chrono-log 570VS,
Havertown, Pennsylvania) as the maximal increase in light
transmittance, expressed as a percentage of that observed with
0.5-ml platelet-poor plasma.
Myocardial platelet content. The previous day, the ani-
mals were anesthetized and ventilated as described; one
femoral vein was catheterized and 51 ml of blood was
withdrawn. The blood was processed as previously described
(10,21), and platelets were isolated and labeled with 99mTc-
hexamethylpropyleneamineoxime (HMPAO) and re-
injected into the animal. Then, anesthesia was stopped, the
femoral cannula was withdrawn and the animals were
allowed to recover, after which they were extubated and
returned to the animal room until the next day. Assuming
that the total blood pool in swine represents 7% of the
animal weight, the labeling fraction in animals allocated to
lamifiban or placebo averaged 3.3  0.2% and 2.9  0.2%
of total blood, respectively (pNS). The labeling efficiency
averaged 55.1  3.2%, and 16.1  1.2 mCi of 99mTc was
injected into each animal (both p  NS between groups).
After 5 h of reperfusion, the LAD was re-occluded, 5 ml
of 10% fluorescein was injected into the left atrium and the
heart was excised, immersed in Ringer’s solution at 4°C and
cut in 5- to 7-mm slices. The slices were weighed, and
transmural myocardial fragments (0.78  0.06 g) were
obtained from the area at risk and the inferior region in the
third slice. The radioactivity of these fragments was counted
for 20 s in a gamma counter (1282-Compugamma, Wallac,
Turku, Finland). Specific activity in reperfused myocardium
(counts/g) was calculated and expressed as a percentage of
the specific activity in the control myocardium.
Myocardial PMN accumulation and infarct size. After
gamma counting, the myocardial samples were stored at
80°C. The samples were processed as previously described
(10,21), and myeloperoxidase (MPO) activity was quanti-
fied after addition of o-dianisidine dihydrochloride and
H2O2, expressed in units defined as the quantity of enzyme
degrading 1 mol peroxide/l per min at 25°C.
Abbreviations and Acronyms
ADP  adenosine diphosphate
CFR  cyclic flow reduction
CO  coronary occlusion
FBS  fetal bovine serum
GP  glycoprotein
HMPAO  hexamethylpropyleneamineoxime
LAD  left anterior descending coronary artery
MPO  myeloperoxidase
PBS  phosphate-buffered saline
PMNs  polymorphonuclear leukocytes
99mTc  technetium-99m
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The remaining slices were weighed and imaged from the
basal side with a video camera under ultraviolet light.
Instead of the third slice, the apical surface of the fourth
slice was imaged. The slices were then incubated at 37°C in
1% triphenyltetrazolium chloride, at pH 7.4, for 10 min,
and imaged under white light. The images were digitized
into 768  576 pixel images (Matrox-IP8 card, Dorval,
Quebec, Canada), and the area at risk and the area of
necrosis were measured semi-automatically (Image Pro-
Plus software, Media Cybernetics, Silver Spring, Maryland)
in the digital images, and infarct size was calculated from
these measurements and the weight of the slices.
Histologic analysis. The slices were fixed in 10% formal-
dehyde, and the fourth slice was processed for histologic
analysis (10,23), stained with hematoxylin and eosin and
examined with an Olympus IMT2 microscope. Infiltration
of PMNs was graded according to a previously described
score (23): 0  absent; 1  scant; 2  intravascular plugs;
and 3  intravascular plugs and PMNs present in the
interstitium. Arteriolar platelet plugs 50 m in diameter
were considered as microemboli (10–12).
Platelet P-selectin expression. In five additional experi-
ments, aliquots of platelet suspensions were incubated for 25
min at room temperature with the anti–P-selectin mono-
clonal antibody KO.2.9 (24), washed with phosphate-
buffered saline (PBS)/0.5% fetal bovine serum (FBS) and
further incubated for 25 min with F(ab)2 fragments of a
goat anti-mouse fluorescein isothiocyanate-conjugated an-
tibody (3.5 g/ml, Caltag, Burlingame, California). Plate-
lets were washed again and resuspended in PBS/0.5% FBS
for flow cytometric analysis. Negative control studies were
performed using an equivalent volume of PBS/2% FBS
instead of the anti–P-selectin antibody. The platelet popu-
lation was analyzed at a low flow rate in a FACScaslibur
flow cytometer (Becton Dickinson, San Jose, California).
Platelets were identified on the basis of forward and
sideward scatter variables in the logarithmic mode. For each
sample, 20  103 platelets were collected. Data were
analyzed with CELLQuest software (Becton Dickinson,
Mansfield, Massachusetts), and the results were expressed as
a percentage of specific antibody-positive platelets, defined
as those with a fluorescence intensity exceeding that of 99%
of negative control platelets.
Stability of labeling with 99mTc/HMPAO and effects on
platelet function. The stability of platelet labeling was
assessed in five additional experiments. Labeled platelets
were resuspended in platelet-poor plasma and distributed
into 1-ml aliquots that were incubated at 33°C. Ninety
minutes, 17 h and 22 h after labeling, these samples were
centrifuged, and the radioactivity in the platelet pellet and in
platelet-poor plasma was counted. To confirm that free
99mTc/HMPAO is rapidly cleared from the blood in our
model, venous blood was withdrawn at these same time
points after 99mTc/platelet re-injection in three additional
animals, and the radioactivity in platelet-poor plasma was
quantified and compared with that in platelet-rich plasma.
Finally, in three animals, the influence of labeling on
platelet P-selectin expression and on platelet aggregation
induced by 10 M ADP was investigated.
Statistical analysis. The study was intended to detect a
large, clinically relevant reduction of infarct size by lamifi-
ban. According to the variability of infarct size in the same
model in previous studies in our laboratory, the sample size
was powered to detect, with alpha and beta probabilities of
0.05 and 0.2, respectively, a reduction in infarct size of 15%
of the area at risk. Statistical analysis was performed using
SPSS software (SPSS Inc., Chicago, Illinois). Comparisons
between groups were performed by the Student t test, with
the exception of those involving histologic scores, which
were subjected to the Mann-Whitney U test. General linear
model analysis of variance for repeated measures was used to
evaluate intra-subject factors (e.g., changes in physiologic
variables along time, differences between control and isch-
emic myocardium), inter-subject factors (e.g., effect of
treatment) and the interaction between both. Data are
expressed as the mean value  SEM. A p value 0.05 was
considered statistically significant.
RESULTS
Hemodynamic data and ventricular arrhythmias. Hemo-
dynamic variables were similar in animals receiving lamifi-
ban or placebo (Table 1). Mean aortic pressure remained
stable during the experiment. At baseline, mean blood flow
at the mid LAD in animals allocated to lamifiban or placebo
was 12  1 ml/min and 15  2 ml/min, respectively (p 
NS). One animal from the placebo group had ventricular
Table 1. Hemodynamic Data
Baseline 5 Min CO 15 Min CO 30 Min CO 55 Min CO 15 Min R 30 Min R 1 h R 3 h R 5 h R
Heart rate (beats/min)
Lamifiban (n  8) 64  4 68  4 64  2 62  4 58  5 71  5 71  8 68  5 74  5 75  5
Placebo (n  8) 61  4 65  7 69  9 64  4 64  3 73  5 74  8 74  10 74  6 75  8
Mean AP (mm Hg)
Lamifiban (n  8) 71  5 58  3 67  5 65  5 70  9 66  6 65  7 63  7 76  9 74  10
Placebo (n  8) 69  7 73  5 79  3 83  4 75  4 68  6 65  7 65  7 64  5 68  6
Data are presented as the mean value  SEM. No significant inter-group differences were observed.
AP  aortic pressure; CO  coronary occlusion; R  reperfusion.
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fibrillation during CO, and three (one receiving lamifiban
and two on placebo) had ventricular fibrillation immediately
after reflow.
Antithrombotic effect of lamifiban. At baseline, the
bleeding time in animals allocated to lamifiban or placebo
was 80  8 s and 91  7 s, respectively (p  NS). In
animals receiving placebo, the bleeding time and ADP-
induced platelet aggregation did not change appreciably
during the experiment. In contrast, lamifiban rapidly pro-
duced a significant prolongation of the bleeding time and a
profound (90% of baseline values) inhibition of platelet
aggregation (Fig. 1). In animals treated with lamifiban, the
development of CFRs after reperfusion was completely
prevented, whereas animals receiving placebo had an aver-
Figure 1. Bleeding time (top) and ex vivo aggregation induced by 10 mol/l of adenosine diphosphate (ADP) (bottom) at several time points of the
experiment. P values refer to the effect of treatment on bleeding time and aggregation according to general linear model analysis of variance for repeated
measures.
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age of 5  1 CFRs (p  0.005). One of the animals in the
placebo group had LAD re-occlusion and was excluded for
further analysis.
Platelet accumulation in reperfused myocardium. Spe-
cific 99mTc/platelet activity in the reperfused myocardium
was 249 26% of that in the control zone (p 0.001). The
magnitude of platelet accumulation in the reperfused myo-
cardium was not correlated with the number of CFRs (r 
0.04) and was similar in animals treated with lamifiban
than in those receiving placebo (288  40% vs. 205  27%,
respectively, p  NS).
Myeloperoxidase activity and infarct size. Activity of
MPO averaged 0.11  0.03 U/g in the control region and
0.46 0.14 U/g in the reperfused myocardium (p 0.037).
Activity of MPO was also not correlated with the number of
CFRs (r  0.05) and was similar in animals receiving
lamifiban and in those receiving placebo (Fig. 2).
The area at risk averaged 11.7  0.9 g, involving 10.0 
0.6% of the ventricular mass, without inter-group differ-
ences. Infarct size averaged 5.6  1.0 g (48.2  7.8% of the
area at risk) and was significantly correlated with specific
99mTc activity (r 0.52, p 0.045) and MPO activity (r
0.66, p  0.01) (Fig. 3), but not with the number of CFRs
(r  0.18, p  NS). Infarct size was also similar in animals
treated with lamifiban and in those receiving placebo (Fig. 4).
Histologic analysis. In the control region, the histologic
appearance of the myocardium was normal in all animals. In
the area at risk, histologic analysis showed the presence of
myocardial edema, as well as cellular infiltration at the
microvessels or in the interstitial space. Histologic scores for
PMN infiltration were similar in animals receiving lamifi-
ban or placebo (1.8  0.5 vs. 1.7  0.3, respectively, p 
NS). There were two arteriolar occlusive plugs in only one
animal from the lamifiban group, suggestive of platelet
microemboli.
Platelet P-selectin expression. In control platelets,
P-selectin expression averaged 8.7  3.2%. Platelets from
the same animals incubated with 100 or 1,000 ng/ml of
lamifiban showed a similar level of P-selectin expression
(9.5  3.6% and 6.8  2.5%, respectively, p  NS), despite
a dose-dependent inhibition—virtually complete at the
highest concentration—of ADP-induced aggregation.
Stability of labeling with 99mTc/HMPAO and effects on
platelet function. The in vitro elution of 99mTc from
labeled platelets was 11  1% at 90 min, 30  3% at 17 h
and 35  7% at 22 h after labeling. At these same time
points, the content of free 99mTc in platelet-poor plasma in
vivo was only 7  1%, 5  1% and 6  1%, respectively, of
that in platelet-rich plasma.
Platelet labeling did not influence platelet aggregation
stimulated with 10 mol/l of ADP (98  8% of that
obtained before labeling, p  NS) and induced a moderate
increase in the proportion of platelets expressing P-selectin
(18.8  4.1% vs. 9.9  2.4% before labeling, p  0.09).
DISCUSSION
This study tested the effect of GP IIb/IIIa blockade with
lamifiban administered during reperfusion on myocardial
platelet and PMN accumulation and on infarct size after
coronary injury followed by transient CO. Although lami-
fiban produced a potent inhibition of platelet function and
prevented the development of CFRs at the injured vessel, it
had no influence on the magnitude of platelet or PMN
accumulation in the reperfused myocardium, nor on infarct
size.
Effect of GP IIb/IIIa blockade on microvascular inju-
ry. Since the description of the “no-reflow” phenomenon
after transient CO (1), attempts have been made to reduce
the severity of microvascular injury during reperfusion, with
disparate results (25–28). Abcximab, administered as an
Figure 2. Activity of myeloperoxidase (MPO) in control and reperfused myocardium.
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adjunct of coronary stenting in patients with acute myocar-
dial infarction, has improved the recovery of tissue perfusion
and regional contractile function (15). Moreover, treatment
with abcximab plus reduced-dose alteplase in patients with
ST-segment elevation infarction has been associated with
an increased rate of ST-segment resolution, a surrogate for
the integrity of microvascular perfusion (3), as compared
with alteplase alone (16).
Some laboratory findings also suggest that platelet GP
IIb/IIIa inhibitors could have direct salutary effects on tissue
Figure 3. Correlation between specific technetium-99m (99mTc) activity (top) and myeloperoxidase (MPO) activity (bottom) in reperfused myocardium,
reflecting platelet and polymorphonuclear leukocytes accumulation, respectively, and infarct size.
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perfusion, as they have been shown to preserve the distal
vasodilatory response after coronary injury and progressive
stenosis (19) and to improve coronary flow and contractile
recovery and reduce PMN accumulation and platelet/PMN
aggregation in reperfused isolated hearts (17,18). Recently,
treatment with the GP IIb/IIIa inhibitor MK-0852 during
coronary reperfusion reduced infarct size in dogs, although
neither contractile function nor blood flow in the area at risk
or the peak reactive hyperemic response of the infarct-
related artery was improved by the treatment (20).
There are several explanations for the discrepancy be-
tween some of these observations and the present results.
First, it is possible that the benefit of GP IIb/IIIa blockade
as an adjunct to stenting (15) was due in part to reduced
embolization of atherothrombotic material, a complication
that may be important after percutaneous intervention (29),
but that is probably irrelevant in our model (10). Second, it
cannot be ruled out that some of the benefit of GP IIb/IIIa
blockade was mediated by a faster recanalization of the
culprit CO and reduced myocardial injury (15,16). Finally,
it is also possible that the beneficial effect of some of these
drugs was due to their ability to interact with receptors other
than GP IIb/IIIa that mediate platelet or PMN adhesion to
the endothelium (30), or even to a cytoprotective mecha-
nism (20).
Mechanisms of platelet deposition in reperfused myocar-
dium. The results concur with a previous study in our
laboratory (10) in which myocardial platelet accumulation
was not associated with the number of CFRs and was also
not lessened by antithrombotic treatment—in that case,
aspirin—despite a reduction in the number of CFRs. These
findings are consistent with a rapid de-aggregation of the
platelets released during CFRs and suggest that microem-
bolization from a mural coronary thrombus is not a prom-
inent cause of platelet deposition in downstream myocar-
dium, and that alternative mechanisms, such as distal
vasoconstriction (31,32), may mediate the deleterious influ-
ence of nonocclusive coronary thrombosis on distal tissue
perfusion, as observed previously (21,33,34).
The finding of an increased platelet content in the
reperfused myocardium and its correlation with infarct size
concur with previous studies (4,5,7,9,10), and the lack of
effect of lamifiban on platelet deposition is in agreement
with previous observations that aspirin failed to reduce the
magnitude of myocardial platelet content after transient CO
(9,10). However, the present finding is at variance with a
previous study showing that GP IIb/IIIa plays a prominent
role in mediating platelet deposition on reperfused mesen-
teric vessels (35). This discrepancy could be explained by
methodologic differences, as well as by the time when
platelet deposition was analyzed. Five hours after reperfu-
sion, when myocardial platelet accumulation is still ongoing
(5), mechanisms other than the interaction between GP
IIb/IIIa and fibrinogen might be involved in the microvas-
cular deposition of platelets. In this respect, a role for
endothelial P-selectin has been demonstrated (36), and
other studies suggest that a platelet–leukocyte interaction
might contribute as well (4,7,10). The fact that lamifiban
apparently had no effect on platelet P-selectin expression
suggests that its failure in reducing myocardial platelet
deposition was not due to a dual effect of the drug on
platelet function (37).
Methodologic considerations and limitations. Platelet
labeling resulted in some degree of activation. However,
virtually complete clearance of altered platelets from the
circulation is expected to occur during the 20 h between
labeling and CO. It also seems unlikely that the temporal
gap between platelet labeling and counting had affected the
results, as additional experiments showed that, after this
period, two-thirds of 99mTc continued to be bound to
platelets, and the content of free plasmatic 99mTc was
negligible.
Figure 4. Area at risk, expressed as a percentage of ventricular mass (left axis) and infarct size, expressed as a percentage of the area at risk (right axis).
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Because the LAD was re-occluded to ensure an accurate
delineation of the area at risk, the coronary vessels could not
be washed to reduce the background activity. However,
several reasons make it unlikely that this strategy prevented
us from detecting a relevant reduction in myocardial platelet
content. First, the ratio of platelet content between the
reperfused and remote myocardium in controls was not very
different to that observed previously (10). Second, the
specific activity in reperfused myocardium after subtracting
the activity in the remote zone was similar in animals
receiving lamifiban or placebo (419 179 counts/g/mCi vs.
345  144 counts/g/mCi of 99mTc injected, respectively,
p  NS). Finally, lamifiban also failed to reduce MPO
activity and infarct size, variables that are closely correlated
with platelet content (4,5,7,9,10).
In the present study, 99mTc and MPO activities were
analyzed in a small myocardial sample. Although a more
comprehensive sampling would have been preferable, this
sampling was representative of a central slice, allowed
accurate analysis of infarct size and spared an additional
central slice for histologic analysis. Moreover, the results on
platelet and leukocyte content were consistent with each
other and with infarct size.
Finally, although it cannot be excluded that with a
substantially larger sample, a significant reduction in infarct
size with lamifiban may have been disclosed, a clinically
relevant effect of this drug under the present experimental
conditions seems unlikely, because infarct size was virtually
identical in both groups, and no trend toward a lower
myocardial platelet or leukocyte content was observed in the
lamifiban-treated animals.
Clinical implications. The present results contradict a
significant beneficial effect of GP IIb/IIIa blockade on
microvascular obstruction after transient CO and support
the hypothesis that the benefits of GP IIb/IIIa inhibitors, as
observed in previous clinical studies, are mainly due to more
rapid coronary reperfusion and reduced myocardial injury or
to a concomitant interaction with receptors other than GP
IIb/IIIa. The results stress the convenience of further
studies exploring alternative mechanisms of platelet accu-
mulation in reperfused microvessels and the effect of their
pharmacologic modification on myocardial salvage after
reperfusion.
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